



Retirement of Dr Adrian Attard Trevisan

Perth, Australia & Malta – 28 June 2018 – Neurotech International Limited (ASX: NTI) (“Neurotech” or the “Company”), wishes to advise that Dr Adrian Attard Trevisan has retired as a non-executive director of the Company.

As the founder and later, director of the Company, Adrian has provided scientific oversight over the Company’s research and development activities over the years. Adrian’s retirement, which takes effect immediately, comes at an opportune time with the publication process of the US Clinical Trial results now at an imminent conclusion, with Adrian observing that the summarised abstract’s conclusions were “the best outcome we could have hoped for... [and] supports our view that Mente can bring substantial change to the management of ASD.”

“Adrian was an integral member of the Company’s Board when the Company was admitted to the Australian Stock Exchange in November 2016,” said Peter O’Connor, Chairman. “This is a natural progression for Adrian since he moved to a non-executive capacity over 12 months ago, and the Board expresses its gratitude towards him for his significant contributions to the Company over this period.”

-ends-

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech’s primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism.

Mente Autism is a clinical-quality EEG device that uses neurofeedback technology to help children with ASD. Designed for home use, Mente Autism helps relax the minds of children on the spectrum which in turns helps them to focus better and engage positively with their environment.

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

For more information please contact:

Fleur Hudson

Company Secretary

fhudson@tribis.com.au

Tel: +61 (8) 9424 9360

Neurotech International Ltd

ABN 73 610 205 402

Level 14, 191 St Georges Terrace

Perth, Western Australia 6060

www.neurotechinternational.com